BlackRock Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

BlackRock Group’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$324K	Buy	55,363 +5,555	+11%	+$30.4K	﹤0.01%	2503
2016 Q3	$263K	Buy	49,808 +2,379	+5%	+$12.8K	﹤0.01%	2535
2016 Q2	$314K	Sell	47,429 -794	-2%	-$4.44K	﹤0.01%	2421
2016 Q1	$225K	Buy	48,223 +12,536	+35%	+$50K	﹤0.01%	2533
2015 Q4	$180K	Sell	35,687 -1,061	-3%	-$5.04K	﹤0.01%	2545
2015 Q3	$129K	Buy	36,748 +4,605	+14%	+$30.8K	﹤0.01%	2645
2015 Q2	$321K	Buy	32,143 +6,601	+26%	+$70.8K	﹤0.01%	2432
2015 Q1	$326K	Buy	25,542 +4,799	+23%	+$61.7K	﹤0.01%	2336
2014 Q4	$293K	Buy	20,743 +1,850	+10%	+$28.7K	﹤0.01%	2404
2014 Q3	$259K	Sell	18,893 -529	-3%	-$8.1K	﹤0.01%	2378
2014 Q2	$299K	Sell	19,422 -17,262	-47%	-$245K	﹤0.01%	2361
2014 Q1	$624K	Buy	36,684 +6,429	+21%	+$97K	﹤0.01%	2165
2013 Q4	$392K	Buy	+30,255	New	+$361K	﹤0.01%	2281

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock Group's KERX Position: Q4 2016 in Review

BlackRock Group increased its Keryx Biopharmaceuticals Inc (KERX) stake by 11% in Q4 2016, buying an estimated $30.4K and bringing the position to 55,363 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #2503.

BlackRock Group first reported a position in KERX in Q4 2013 and has held it in 13 quarters since. The position peaked at $624K in Q1 2014. 123 funds tracked by Wall St. Rank hold KERX as of Q4 2016.

BlackRock Group held 55,363 shares of Keryx Biopharmaceuticals Inc worth $324K as of Q4 2016.
BlackRock Group bought 5,555 Keryx Biopharmaceuticals Inc shares in Q4 2016, an estimated $30.4K.
Keryx Biopharmaceuticals Inc made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2503 holding.
BlackRock Group first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and has held it in 13 quarters since.
BlackRock Group's Keryx Biopharmaceuticals Inc position peaked at $624K in Q1 2014.
123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.